Feed RCUS
RC

Arcus Biosciences, Inc.

RCUS · NYSE

$24.08 -2.05% (-$0.51)
1M -18.57%
Market Cap $3.03B
P/E Ratio -
Div. Yield -
ROE 87.98%

Bulios Fair Price

$33.67

39.8% upside

Current Price

$24.08

Undervalued Fair Value Overvalued

According to Bulios Fair Price, RCUS is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
0/9
Valuation
9 /100
Expensive
P/B 6.53x
P/S 25.89x
EV/EBITDA N/A
Growth
82 /100
Growing
Book val. growth 1.34%
Rev. growth 30.16%
FCF growth N/A
Profitability
20 /100
Weak
Net margin 386.33%
Op. margin 415.39%
FCF margin 405.98%
Quality
2 /100
Poor
ROE 87.98%
ROA 48.92%
Asset turnover 0.13x
Debt
69 /100
Low
Current ratio 3.82x
Int. coverage -18.65x
Debt/Equity 0.25x
Stability
53 /100
Moderate
Rev. volatility 69.66%
EPS volatility 19.18%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about RCUS
Online

About the company

Arcus Biosciences, Inc. (RCUS) is an American biotechnology company focused on researching and developing new drugs for the treatment of oncology and inflammatory diseases. The company specializes in discovering innovative therapeutic drugs based on immunotherapy and cell growth pathway inhibition. Its research and development efforts are aimed at boosting the immune system's ability to fight against cancer cells and inflammatory processes. Arcus Biosciences collaborates with pharmaceutical companies and academic institutions in the discovery and development of new drugs and therapies. The company aims to bring innovative treatment options to patients facing challenging and difficult-to-treat diseases. Arcus Biosciences, Inc. is recognized for its research potential and influential position in the field of immuno-oncology. Arcus Biosciences, Inc. (RCUS) shares may represent an attractive investment opportunity for investors monitoring the biotechnology sector and seeking investments in a company with an innovative portfolio of research in oncology and immunotherapy.

Sector

Healthcare

Industry

Biotechnology

CEO

Terry J. Rosen

Employees

601

Headquarters

Hayward

Upcoming events

27 OCT

Earnings

Upcoming earnings report

42d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.